Evidence-Based Complementary and Alternative Medicine
Volume 2018 (2018), Article ID 6527549, 14 pages
https://doi.org/10.1155/2018/6527549

Research Article

Simultaneous Evaluation of the Influence of Panax ginseng on the Pharmacokinetics of Three Diester Alkaloids after Oral Administration of Aconiti Lateralis Radix in Rats Using UHPLC/QQQ-MS/MS

Liang Yang, Yuguang Wang, Guangyao Huang, Jian Li, Zhaoyan Zhang, Zengchun Ma, and Yue Gao

Beijing Institution of Radiation Medicine, Beijing 100850, China

Correspondence should be addressed to Yue Gao; gaoyue@bmi.ac.cn

Received 6 July 2018; Revised 2 November 2018; Accepted 18 November 2018; Published 9 December 2018

Academic Editor: José L. Rios

Copyright © 2018 Liang Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Objectives. To investigate whether Panax ginseng (P. ginseng) could affect the metabolism of Diester Alkaloids (DAs) derived from Aconiti Lateralis Radix in vivo. Methods and Results. 24 male Sprague-Dawley rats were randomized for 7-day treatment with P. ginseng (low, middle, and high), or vehicle. Aconiti Lateralis Radix was administered orally to each group on the 8th day. Plasma samples were collected, and Xevo TQ-S was used to detect the concentration of aconitine, mesaconitine, and hypaconitine in plasma. We describe a fast and reproducible method to detect the concentration of aconitine, mesaconitine, and hypaconitine in plasma. Compared to the control group, the of three DAs increased in both the middle and high dosing groups. The Vz/F of three DAs in these groups as well as the CLz/F of aconitine in all P. ginseng groups and the CLz/F of mesaconitine and hypaconitine in P. ginseng middle and high groups were decreased compared to the control group. Conclusion. Orally administrated P. ginseng potentially inhibits the metabolism of DAs from Aconiti Lateralis Radix in rats.

1. Introduction

Panax ginseng C. A. Mey (referred as P. ginseng in this study) and Aconiti Lateralis Radix are two traditional Chinese medicines that have a long history of successful application in the clinic [1–3].

P. ginseng has been used for the treatment of various diseases such as liver dysfunction [4], hypertension [5], and cerebrovascular disease [6] in China, Japan, and Korea. Various ginsenosides such as Rg1, Rb1, Rc, Rd, Rg3, Rh1, and Rf have all been found to be important constituents in P. ginseng extracts [7–10]. Aconiti Lateralis Radix is traditional Chinese medicine famed for its toxicity and contains a range of diverse alkaloids such as aconitine, mesaconitine, hypaconitine, and benzoylaconitine among many others [11]. Aconitine, mesaconitine, and hypaconitine, which are classed as DAs, have been shown to be the major toxic components in Aconiti Lateralis Radix and have been known to exert both potent cardiac toxicity and neurotoxicity in several studies [12, 13].

Routes of administration vary when a combination of P. ginseng with Aconiti Lateralis Radix is required, including the two traditional routes, by injection and by mouth [1, 2]. These routes are commonly used for a range of disorders, most notable in the treatment of heart failure and rescuing hemorrhagic shock [14–19]. Although this treatment is often successful, overdose is common among patients. New measures to reduce this risk are now in place including more strictly controlled usage to limit cardiac toxicity and neurotoxicity. To date, the mode of action of this toxicity is unknown; however, several hypotheses have been developed. It was found that toxicity was reduced in doses that had increased levels of monoester alkaloids, while toxicity was directly correlated to an increase in DAs [20, 21].

In our previous work, we reasoned that P. ginseng could have a direct effect on the metabolism of these DAs (aconitine, mesaconitine, and hypaconitine) in vitro. Furthermore, we speculated that metabolism stemmed from oxidative transformations mediated by CYP3A4, which was confirmed to be the primary sub-cytochrome P450s (CYPs) for phase 1 metabolism of DAs. And researchers also found that biological activities and pharmacokinetics difference of three representative alkaloids: aconitine, benzoylaconine, and aconine were observed after oral administration in rats [22]. Though aconitine, mesaconitine, and hypaconitine were all belonging to DAs, the structural involvement of sub-CYPs in the metabolism and toxicity of them [23] was not entirely consistent. Zhang Q et al. investigated the pharmacokinetic difference of alkaloids in rats after oral administration of decoction of Aconiti Lateralis Radix. They found that different preparative methods resulted in significant difference on exposure and pharmacokinetic characteristics of alkaloids [24]. Therefore, we wanted to further evaluate whether P. ginseng directly influences the metabolism of DAs in vivo, which to the best of our knowledge has yet to be studied.

The present study therefore aims to investigate the pharmacokinetic difference between aconitine, mesaconitine, and hypaconitine after exposure to P. ginseng in rats.

2. Materials and Methods

2.1. Materials and Chemicals

P. ginseng was purchased from qiancao Group Co., Ltd. (Beijing, China). Aconiti Lateralis Radix was produced by Tongrentang (Beijing, China). Carbamazepines were purchased from Sigma-Aldrich Co., Ltd. (Darmstadt, Germany). Ginsenoside Rf (CAS:52286-58-5), Notoginsenoside R2 (CAS:80418-25-3), Ginsenoside Rg2 (CAS:52286-74-5), Ginsenoside Rh1 (CAS:63223-86-9), Ginsenoside Rg3 (CAS:14197-60-5), Ginsenoside Rb3 (CAS: 68406-26-8 ), Chikusetsusaponin IVa (51415-02-2), Ginsenoside F2 (CAS:62025-49-4), Ginsenoside Rd (CAS:52705-93-8), Ginsenoside Rg6 (CAS:147419-93-0), Aconitine (CAS: 302-27-2), Mesaconitine (CAS: 2752-64-9), and Hypaconitine (CAS: 6900-87-4) were purchased from EFEBIO Co., Ltd. (Shanghai, China). Acetonitrile and Methanol (HPLC grade) were purchased from Fisher Scientific Company Inc. (Boston, USA).

2.2. The Preparation of P. ginseng and Aconiti Lateralis Radix Extract

P. ginseng (300 g) was soaked in 2.4 L doubly distilled water and boiled for 1 hour. The filtrate was collected and previous step was repeated. The combined filtrates were concentrated by rotary evaporation to afford extracts of 0.5 g/ml (according to the concentration of the crude drugs). The same protocol was used to obtain the extract of Aconiti Lateralis Radix. Extracts were centrifuged at 12,000g for 10 min, the supernatant transferred to a clean centrifuge tube and stored at -20°C.

2.3. The Preparation of Reference Solution

Stock solutions were prepared by dissolving accurately weighed reference compounds in methanol at concentrations 1mg/ml individually. Then working solutions were diluted with 50% methanol respectively at concentration of 10 μg/ml, and centrifuged at 12,000 g for 10 min. Then samples were filtered through a 0.22 μm micropore membrane. A 5 μL volume of supernatant was injected into LC-MS system for analysis.

2.4. The Qualitative Analysis of Herb Extracts

UPLC/Q-TOF-MS (Waters, USA) was used to detect the target components of herb extracts. The extracts were centrifuged at 12,000g for 10 min, diluted to a specific concentration, and filtered through a 0.22 μm Micropore membrane. A 5 μl injection was used for subsequent analysis.

Chromatographic separation was conducted on Waters ACQUITY UPLC HSS T3 1.8 μm column (2.1 mm × 100 mm) and the column temperature was 45°C. The flow rate was 0.4ml/min. Room temperature was 20 ± 2°C. Phase A consisted of water and 0.1% formic acid (v/v) and phase B consisted of acetonitrile (ACN) 0.1% formic acid (v/v). Column separation for Aconiti Lateralis Radix extract was performed by gradient elution program: 0-1 min, 10% B; 2-25 min, 90% B; 26-28 min, 10% B; 30 min, 10% B. Column separation for P. ginseng extract was performed by gradient elution program: 0-1 min, 2.0-20% B; 1-27 min, 20-50% B; 29-30 min, 2% B.

Electrospray ionization (ESI) and positive ion V mode were used to determine the components of Aconiti Lateralis Radix extract. Negative ion V mode was used to determine the components of P. ginseng extract. The main parameters for mass spectrum were set as follows: capillary voltage: 3.0 kv; sample cone: 40 v; source temperature: 100°C; desolvation temperature: 350°C; cone gas flow: 450 L/h; desolvation gas flow: 900 L/h; injection volume: 5 μl. The composition identification was done by combining reference substance and molecular weight deviation.

2.5. Animals and Treatments

24 male Sprague-Dawley (SD) rats (180-220 g) were obtained from the animal experiment center of the Academy of Military Medical Science of People’s license (Beijing, China): SCXK (army)-2012-0004. The environment of raising animals was controlled (room temperature: 22 ± 2°C, humidity: 50 ± 5%, 12 h dark-light cycle). All of the animal experiments were performed in accordance with the guidelines of European community, approved by Institution of Animal Care and Use Committee, Academy of Military Medical Science (IACUC-AMMS). All animals were kept in these environments for 5 days before experiments.

Rats were randomly divided into 4 groups: control group, P. ginseng (low, middle, and high) group. 7 days of oral administration of P. ginseng extract was administered at a dosage of 0.1, 1, 10 g/kg for P. ginseng group (low, middle, and high), respectively, once daily. Distilled water was administered at a dosage of 2 ml/kg for control group, simultaneously. On the 8th day, Aconiti Lateralis Radix extracts (1 g/kg) were orally administered to all groups. 0.5 ml plasma samples were collected in 1.5 ml centrifuge tubes (containing heparin sodium) at 10, 30, 60, 90, 120, 240, 480, 720, 1440, and 2880 min. All plasma samples were centrifuged for 15 min at 4000g. The supernatant was separated to another 1.5 ml centrifuge tubes and stored at -20°C.

2.6. Preparation of Plasma Samples and Method Validation

Liquid-liquid extraction (ethyl acetate) and protein precipitation (50% acetonitrile plus 50% methanol) methods were compared to determine the best method to prepare the plasma sample. Liquid-liquid extraction method was chosen, due to reproducibly high recovery rates. The details of the extraction are as follows: 10 μL carbamazepine (IS) was added to 90 μL plasma, spiked with 400 μL ethyl acetate and the mixture vortexed for 15 seconds. After centrifugation at 12,000g for 10 min, the supernatant was transferred to another 1.5 mL centrifuge tube and dried under a stream of nitrogen at 37°C. The residue was redissolved in 100 μL 50% acetonitrile and centrifuged at 12,000g for 10 min and filtered through a 0.22 μm Micropore membrane. A 5 μL volume of supernatant was injected into LC-MS system for analysis.

Plasma from rats without any processing was used to evaluate the detection methods. 0.1, 0.25, 0.5, 1, 2.5, 5, 10 ng/ml were chosen to calculate standards curve. 0.1, 0.4, 4, 8 ng/mL were selected as the QC sample (n = 4) with repeated operations used to calculate accuracy and precision of the detection method. The data was acquired after keeping the samples at either +4°C 24 hours or room temperature (about 25°C) for 24 hours as well as using freeze-thaw methods (three times) to evaluate stability. Recovery of the developed methods was calculated by the following formula: recovery = measured value/ theoretical value × 100%.

2.7. Xevo TQ-S Conditions

Xevo TQ-S (Waters, USA) was utilized for the analysis of all biological samples. Chromatographic separation was conducted on Waters ACQUITY UPLC HSS T3 1.8 μm column (2.1 mm × 100 mm). Column temperature was 45°C and the flow rate was 0.5ml/min. Room temperature was 20 ± 2°C. Phase A consisted of water and 0.1% formic acid (v/v), and phase B consisted of acetonitrile (ACN) 0.1% formic acid (v/v). Column separation was performed by gradient elution: 0-0.5 min, 10% B; 1-2 min, 90% B; 4 min, 10% B.

Electrospray ionization (ESI) and positive ion V mode were used to determine the samples. The main parameters for mass spectrum were set as follows: capillary voltage: 3.5 kv; sample cone: 60 v; source offset: 50 v; source temperature: 150°C; desolvation temperature: 350°C; cone gas flow: 150 L/h; desolvation gas flow: 650 L/h; injection volume: 5 μL.

2.8. Statistical Analysis

The data was acquired and analyzed by XEVO-QT-S (Waters). The pharmacokinetic parameters were analyzed by DAS pharmacokinetic program (Version 2.0). SAS statistical software was used to determine the difference between each group. All data was presented as mean ± SD, and P<0.05 was considered statistically significant. The figures were processed and displayed by GraphPad prism software (Version 5.01).

3. Results

3.1. The Qualitative Analysis of Herb Extracts

The main components in P. ginseng included ginsenoside Rf, Rg2, Rg3, Rb3, Rh1, Rd, Rg6, F2, notoginsenoside R2, and chikusetsusaponin IVa (Figure 1 and Table 1). The positive ion peak chromatograms of aconitine, mesaconitine, and hypaconitine in Aconiti Lateralis Radix by UPLC-Q/TOF-MS were shown in Figure 2 and clearly show that aconitine, mesaconitine, and hypaconitine were successfully extracted from Aconiti Lateralis Radix. The assigned identity, retention time, molecular formula, theoretical mass/Da, mean measured mass/Da, and mass accuracy (1.0 × 10⁻⁶) of herb extract were shown in Tables 1 and 2.

Table 1: Main compounds detected in P. ginseng extracts.

Peak no.
Assigned identity
Rt
 Molecular formula
[M-H]⁻([M-H+HCOOH]⁻)

/min
 Theoretical mass/Da
Mean measured mass/Da
Mass accuracy /10⁻⁶

1
ginsenoside Rf
9.96
C₄₂H₇₂O₁₄
845.4899
845.495
6.03

2
notoginsenoside R2
10.89
C₄₁H₇₀O₁₃
815.4810
815.4793
-2.08

3
ginsenoside Rg2
11.80
C₄₂H₇₂O₁₃
829.4950
829.4910
-4.82

4
ginsenoside Rh1
11.93
C₃₆H₆₂O₉
683.4370
683.4380
1.46

5
ginsenoside Rb3
14.69
C₅₃H₉₀O₂₂
1077.5846
1077.5762
-7.80

6
chikusetsusaponin IVa
15.21
C₄₂H₆₆O₁₄
793.4374
793.4314
-7.56

7
ginsenoside Rd
16.02
C₄₈H₈₂O₁₈
991.3988
991.3899
-8.98

8
ginsenoside Rg6
18.82
C₄₂H₇₀O₁₂
811.4844
811.4838
-0.74

9
ginsenoside F2
21.36
C₄₂H₇₂O₁₃
783.4895
783.4824
-9.06

10
ginsenoside Rg3
22.88
C₄₂H₇₂O₁₃
783.4895
783.4904
1.15

Table 2: Main compounds detected in Aconiti Lateralis Radix extracts.

Peak no.
Assigned identity
Rt
Molecular formula
[M+H]⁺

/min
 Theoretical mass/Da
Mean measured mass/Da
Mass accuracy /×10⁻⁶

1
inositol
0.51
C₆H₁₂O₆
180.0643
180.0648
-2.78

2
fuziline
3.01
C₂₄H₃₉NO₇
454.2805
454.2811
-1.32

3
fuziline
3.15
C₂₄H₃₉NO₇
454.2805
454.2837
-7.04

4
bullatine
3.82
C₂₄H₃₉NO₆
438.2856
438.2819
8.44

5
talatisamine
4.05
C₂₄H₃₉NO₅
422.2906
422.2905
0.24

6
benzoylmesaconine
8.32
C₃₁H₄₃NO₁₀
590.2695
590.2696
-0.17

7
chasmanine
9.51
C₂₅H₄₁NO₆
452.3012
452.3055
-9.51

8
mesaconitine
12.61
C₃₃H₄₅NO₁₁
632.3071
632.3021
7.91

9
hypaconitine
15.92
C₃₃H₄₅NO₁₀
616.3122
616.3136
-0.65

10
aconitine
15.93
C₃₄H₄₇NO₁₁
646.3227
646.3220
1.08

11
aldohypaconitine
18.05
C₃₃H₄₃NO₁₁
630.2914
630.2971
-9.04

(a)

(b)

Figure 1: The negative ion peak chromatograms of P. ginseng extracts and reference substances of main components by UPLC-Q/TOF-MS. (a) Reference substances and (b) P. ginseng extracts (1: ginsenoside Rf; 2: notoginsenoside R2; 3: ginsenoside Rg2; 4: ginsenoside Rh1; 5: ginsenoside Rb3; 6: chikusetsusaponin IVa; 7: ginsenoside Rd; 8: ginsenoside Rg6; 9: ginsenoside F2; 10: ginsenoside Rg3).

(a)

(b)

(c)

(d)

Figure 2: The positive ion peak chromatograms of aconitine, mesaconitine, hypaconitine, and Aconiti Lateralis Radix extracts by UPLC-Q/TOF-MS. (a) aconitine: 646.3220 (m/z); (b) mesaconitine: 632.3021(m/z); (c) hypaconitine: 616.3136 (m/z); and (d) Aconiti Lateralis Radix extracts (1: inositol; 2: fuziline; 3: fuziline; 4: bullatine; 5: talatisamine; 6: benzoylmesaconine; 7: chasmanine; 8: mesaconitine; 9/10: hypaconitine/aconitine; 11: aldohypaconitine).

3.2. Method Validation

3.2.1. Selectivity and Specificity

The ion pair of relevant compounds were 646.17>586.03 (aconitine), 632.25>571.92 (mesaconitine), and 616.30>555.97 (hypaconitine) with carbamazepine (237.07>194.03) used as the internal standards (IS). The molecular weight and retention time of each compound in the sample are shown in Figure 4, with these peaks not observed for the blank control sample (Figure 3). The limit of detection (LOD) and the lowest limit of quantification (LLOQ) were defined by signal-to-noise ratio method. LOD should be three times of the noise level (S/N >3). LLOQ should be ten times of the noise level (S/N >10). The LOD and LLOQ of three DAs in this experiment were 0.025 ng/ml and 0.1 ng/ml, respectively (Table 3).

Table 3: Standard curves, linear range, correlation coefficient, LOD, and LLOQ of aconitine, mesaconitine, and hypaconitine in rat plasma.

Name
Standard curves
Linear range
R²
LLOQ
LOD

(ng/mL)
(ng/mL)
(ng/mL)

Aconitine
y = 0.3651x + 0.0210
0.1-10
0.9997
0.1
0.025

Mesaconitine
y = 0.7952x + 0.0218
0.1-10
0.9987
0.1
0.025

Hypaconitine
y = 0.718x + 0.0605
0.1-10
0.9970
0.1
0.025

(a)

(b)

(c)

(d)

Figure 3: The positive ion peak chromatograms of aconitine, mesaconitine, hypaconitine, and carbamazepine (IS) in blank group by XEVO-QT-S. (a) Carbamazepine, the ion pair 237.07>194.03. (b) Hypaconitine, the ion pair 616.30>555.97. (c) Mesaconitine, the ion pair 632.25>571.92. (d) Aconitine, the ion pair 646.17>586.03.

(a)

(b)

(c)

(d)

Figure 4: Positive ion peak chromatograms of aconitine, mesaconitine, hypaconitine, and carbamazepine (IS) in biology sample by XEVO-QT-S. (a) Carbamazepine, the ion pair 237.07>194.03. (b) Hypaconitine, the ion pair 616.30>555.97. (c) Mesaconitine, the ion pair 632.25>571.92. (d) Aconitine, the ion pair 646.17>586.03.

3.2.2. Standard Curves and Linearity

The standard curve and correlation coefficient of the three components in the selected concentration range 0.1-10 ng/mL are shown in Table 3 and Figure 5.

(a)

(b)

(c)

Figure 5: Standard curves of aconitine, mesaconitine, and hypaconitine in biological samples. (a) aconitine, Y = 0.3651X + 0.021, R² = 0.9997; (b) mesaconitine, Y = 0.7952X + 0.0218, R² = 0.9987; (c) hypaconitine, Y = 0.718X + 0.0605, R² = 0.9970.

Three standard curves for aconitine, mesaconitine, and hypaconitine were y = 0.3651x + 0.021, y = 0.7952x + 0.0218, and y = 0.718x + 0.0605, respectively. The correlation coefficient was 0.9997 (aconitine), 0.9987 (mesaconitine), and 0.9970 (hypaconitine).

3.2.3. Precision and Accuracy

The precision and accuracy of the detection of three compounds in both intra- and interday at the linear range are shown in Table 4. Four QC concentrations (0.1, 0.4, 4, 8 ng/mL) were analyzed for each compound. The average precision and accuracy of intraday samples ranged from 2.20% to 7.06% and from 91.18 ± 5.49% to 111.64 ± 2.45%, respectively. The average precision and accuracy of interday ranged from 1.98% to 15.88% and from 83.09 ± 6.75% to 105.48 ± 3.64%, respectively, which proved that the methods had a good accuracy and precision.

Table 4: Intra- and Interday precision and accuracy of these standard curves.

Name
QC conc.
Intraday
Interday

Concentration
RSD
Accuracy
Concentration
RSD
Accuracy

(ng/mL)
(ng/mL)
(%)
(%)
(ng/mL)
(%)
(%)

Aconitine
0.10
0.09 ± 0.01
6.03
91.18 ± 5.49
0.08 ± 0.01
8.12
83.09 ± 6.75

0.40
0.39 ± 0.01
3.31
98.05 ± 3.24
0.40 ± 0.02
4.06
100.49 ± 4.08

4.00
4.30 ± 0.30
7.06
107.38 ± 7.58
4.00 ± 0.08
1.98
99.92 ± 1.98

8.00
8.02 ± 0.36
4.45
100.25 ± 4.46
7.94 ± 0.19
2.35
99.28 ± 2.34

Mesaconitine
0.10
0.11 ± 0.00
2.20
111.64 ± 2.45
0.10 ± 0.02
15.88
100.71 ± 15.99

0.40
0.40 ± 0.01
3.73
100.26 ± 3.74
0.38 ± 0.03
7.86
95.08 ± 7.47

4.00
3.96 ± 0.23
5.76
99.08 ± 5.7
3.98 ± 0.24
6.10
99.44 ± 6.06

8.00
7.93 ± 0.28
3.57
99.07 ± 3.54
7.94 ± 0.25
3.15
99.30 ± 3.13

Hypaconitine
0.10
0.10 ± 0.01
5.79
104.52 ± 6.05
0.11 ± 0.00
3.45
105.48 ± 3.64

0.40
0.38 ± 0.01
3.39
95.55 ± 3.24
0.39 ± 0.01
3.82
97.76 ± 3.74

4.00
4.17 ± 0.27
6.36
104.26 ± 6.63
4.06 ± 0.18
4.51
101.58 ± 4.58

8.00
8.02 ± 0.36
4.45
100.25 ± 4.46
7.94 ± 0.19
2.35
99.28 ± 2.34

3.2.4. Stability and Recovery

The stability data of detected methods were shown in Table 5. The stability of three compounds in 4°C and room temperature (about 25°C) within 24 hours are shown in Table 5(a), with the accuracies ranging from 97.02 ± 9.18% to 101.57 ± 1.29% and from 93.68 ± 2.77% to 100.64 ± 3.60%, respectively. The stability of freeze-thawing the samples is shown in Table 5(b). The RSDs of the accuracy were less than 10.10%. The data displayed that the three compounds had good overall stability.

Table 5

(a) The stability at 4°C and room temperature of detected methods.

Name
QC conc.
4°C temperature stability (24 h)
Room temperature stability (24 h)

(ng/mL)
Concentration (ng/mL)
RSD (%)
Accuracy (%)
Concentration (ng/mL)
RSD (%)
Accuracy (%)

Aconitine
0.40
0.40 ± 0.01
2.16
99.65 ± 2.16
0.40 ± 0.01
2.51
100.49 ± 2.52

4.00
3.96 ± 0.4
10.10
98.98 ± 9.99
3.85 ± 0.13
3.38
96.29 ± 3.26

8.00
8.13 ± 0.1
1.27
101.57 ± 1.29
7.81 ± 0.36
4.64
97.66 ± 4.54

Mesaconitine
0.40
0.40 ± 0.03
8.71
100.28 ± 8.73
0.39 ± 0.03
7.21
96.34 ± 6.95

4.00
3.88 ± 0.37
9.47
97.02 ± 9.18
3.75 ± 0.11
2.95
93.68 ± 2.77

8.00
7.95 ± 0.37
4.59
99.43 ± 4.57
8.06 ± 0.38
4.74
100.72 ± 4.78

Hypaconitine
0.40
0.39 ± 0.01
2.41
97.44 ± 2.35
0.40 ± 0.01
2.51
100.49 ± 2.52

4.00
4.20 ± 0.22
5.23
104.96 ± 5.49
3.95 ± 0.17
4.35
98.72 ± 4.30

8.00
8.09 ± 0.39
4.76
101.13 ± 4.82
8.05 ± 0.29
3.58
100.64 ± 3.60

(b) The stability at freeze-thaw of detected methods.

Name
QC conc.
Freeze-thaw

(ng/mL)
Concentration (ng/mL)
RSD (%)
Accuracy (%)

Aconitine
0.40
0.40 ± 0.01
2.06
99.71 ± 2.06

4.00
4.00 ± 0.25
6.24
99.91 ± 6.23

8.00
8.02 ± 0.15
1.87
100.22 ± 1.87

Mesaconitine
0.40
0.38 ± 0.03
7.69
95.09 ± 7.31

4.00
4.01 ± 0.36
8.89
100.37 ± 8.92

8.00
7.97 ± 0.27
3.36
99.59 ± 3.35

Hypaconitine
0.40
0.40 ± 0.01
2.06
99.71 ± 2.06

4.00
4.01 ± 0.24
6.01
100.26 ± 6.03

8.00
8.19 ± 0.26
3.12
102.33 ± 3.19

The recovery of the developed methods was shown in Table 6. The extraction rate for each component at three QC concentrations ranged from 97.74% to 105.02%, and the RSDs ranged from 2.17% to 9.67%.

Table 6: Recovery of the developed methods.

Name
QC conc. (ng/mL)
Recovery (Mean ± SD)
RSD (%)

Aconitine
0.40
99.29 ± 3.88
3.90

4.00
104.26 ± 9.40
9.02

8.00
102.00 ± 6.29
6.17

Mesaconitine
0.40
101.67 ± 9.83
9.67

4.00
105.02 ± 8.19
7.80

8.00
98.93 ± 5.25
5.30

Hypaconitine
0.40
97.74 ± 3.07
3.14

4.00
104.56 ± 6.28
6.01

8.00
103.32 ± 2.24
2.17

3.2.5. The Effect of P. ginseng on the Metabolism of Aconitine, Mesaconitine, and Hypaconitine in Rats

The blood concentration-time curves of aconitine, mesaconitine, and hypaconitine are shown in Figure 6. The pharmacokinetic parameters of each compound in the four groups were shown in Tables 7–9. The of the three DAs were increased in P. ginseng middle group (61.05 ± 12.82 μg/Lh for aconitine, 82.45 ± 18.57 μg/Lh for mesaconitine, and 70.71 ± 7.55 μg/Lh for hypaconitine) and high group (162.98 ± 48.50 μg/Lh for aconitine, 126.07 ± 44.93 μg/Lh for mesaconitine, and 71.75 ± 22.2 μg/Lh for hypaconitine) when compared to the of the control group (40.77 ± 9.71 μg/Lh for aconitine, 51.24 ± 21.48 μg/Lh for mesaconitine, and 48.12 ± 24.59 μg/Lh for hypaconitine).

Table 7: Effect of P. ginseng on the pharmacokinetics of aconitine at day 7 after administration.

Aconitine
Control
P. ginseng-low
P. ginseng-middle
P. ginseng-high

(μg/Lh)
40.77 ± 9.71
58 ± 13.02
61.05 ± 12.82
162.98 ± 48.50

(μg/Lh)
46.20 ± 9.57
60.32 ± 12.99
61.49 ± 13.16
228.56 ± 100.03

(h)
10.71 ± 4.78
10.10 ± 3.72
6.14 ± 1.18
26.49 ± 23.27

(h)
2.67 ± 2.91
4.00 ± 3.27
2.11 ± 2.97
1.33 ± 0.41

/F (L/kg)
3345.75 ± 1370.68
2480.3 ± 944.53
1458.36 ± 189.64
1547.04 ± 685.53

/F (L/h/Kg)
225.85 ± 54.74
172.11 ± 35.46
169.57 ± 40.27
51.09 ± 21.00

(μg/L)
3.88 ± 0.92
5.03 ± 3.02
5.79 ± 2.80
11.53 ± 3.49

Note: Compared with the control group, <0.05, <0.01.

Table 8: Effect of P. ginseng on the pharmacokinetics of mesaconitine at day 7 after administration.

Mesaconitine
Control
P. ginseng-low
P. ginseng-middle
P. ginseng-high

(μg/Lh)
51.24 ± 21.48
65.53 ± 9.06
82.45 ± 18.57
126.07 ± 44.93

(μg/Lh)
58.66 ± 27.59
71.36 ± 12.85
87.1 ± 21.80
138.96 ± 55.36

(h)
13.17 ± 10.45
12.12 ± 6.11
10.31 ± 3.00
12.56 ± 4.48

(h)
1.58 ± 1.32
0.89 ± 0.60
1.83 ± 1.21
2.20 ± 1.98

/F (L/kg)
3146.87 ± 1886.84
2386.47 ± 832.39
1745.91 ± 488.37
1395.19 ± 472.75

/F (L/h/Kg)
217.47 ± 130.54
144.13 ± 26.77
120.75 ± 29.09
81.37 ± 29.62

(μg/L)
5.48 ± 2.61
4.66 ± 1.03
6.02 ± 1.63
8.94 ± 2.33

Note: Compared with the control group, <0.05, <0.01.

Table 9: Effect of P. ginseng on the pharmacokinetics of hypaconitine at day 7 after administration.

Hypaconitine
Control
P. ginseng-low
P. ginseng-middle
P. ginseng-high

(μg/Lh)
48.12 ± 24.59
65.64 ± 13.14
70.71 ± 7.55
71.75 ± 22.2

(μg/Lh)
60.16 ± 28.03
70.68 ± 8.89
71.49 ± 8.07
77.26 ± 25.15

t1/2z (h)
14.11 ± 5.41
9.70 ± 3.55
6.97 ± 1.77
11.67 ± 4.21

Tmax (h)
2.67 ± 2.91
3.61 ± 3.47
2.53 ± 3.01
1.83 ± 1.29

Vz/F (L/kg)
3881.01 ± 1698.43
2023.85 ± 818.73
1400.22 ± 272.41
2283.28 ± 953.88

CLz/F (L/h/Kg)
204.16 ± 98.97
143.1 ± 15.52
141.34 ± 15.57
139.20 ± 37.51

Cmax (μg/L)
4.63 ± 1.96
4.02 ± 2.01
5.85 ± 2.71
4.87 ± 1.36

Note: Compared with the control group, <0.05, <0.01.

(a)

(b)

(c)

Figure 6: The curves of concentration and time of aconitine, mesaconitine, and hypaconitine in rat’s plasma. (a) Aconitine, (b) mesaconitine, and (c) hypaconitine.

The Vz/F of the DAs in the P. ginseng middle group (1458.36 ± 189.64 L/kg for aconitine, 1745.91 ± 488.37 L/kg for mesaconitine, and 1400.22 ± 272.41 L/kg for hypaconitine ) and high group (1547.04 ± 685.53 L/kg for aconitine, 1395.19 ± 472.75 L/kg for mesaconitine, and 2283.28 ± 953.88 L/kg for hypaconitine) were decreased when compared to the control (3345.75 ± 1370.68 L/kg for aconitine, 3146.87 ± 1886.84 L/kg for mesaconitine, and 3881.01 ± 1698.43 for hypaconitine).

The CLz/F of aconitine in all P. ginseng groups were low (172.11 ± 35.46 L/h/Kg), middle (169.57 ± 40.27 L/h/Kg), and high (51.09 ± 21.00 L/h/Kg). The CLz/F of mesaconitine and hypaconitine in P. ginseng middle (120.75 ± 29.09 L/h/Kg for mesaconitine, 141.34 ± 15.57 L/h/Kg for hypaconitine) and high groups (81.37 ± 29.62 L/h/Kg for mesaconitine, 139.20 ± 37.51 L/h/Kg for hypaconitine) were decreased in comparison to the control group (225.85 ± 54.74 L/h/Kg for aconitine, 217.47 ± 130.54 L/h/Kg for mesaconitine, and 204.16 ± 98.97 L/h/Kg for hypaconitine ).

The of aconitine (11.53 ± 3.49 μg/L) and mesaconitine (8.94 ± 2.33 μg/L) increased in P. ginseng high groups compared to control (3.88 ± 0.92 μg/L for aconitine, 5.48 ± 2.61 μg/L for mesaconitine), whereas the of hypaconitine did not change in all groups. The t1/2 of three alkaloids of all groups had no significant difference.

4. Discussion

P. ginseng and Aconiti Lateralis Radix are widely used in traditional medicine [25] in many Asian countries such as China, Japan, India, and Korea. P. ginseng, which displays immune enhancement [26], anticancer [27], anti-inflammatory [28], and antioxidant activities [29], can increase the efficacy of Aconiti Lateralis Radix [3, 25, 30].

Aconiti Lateralis Radix is the root of the Aconite and works to excite central nervous system as well as improve heart function in cases of heart failure [12, 31]. Reports have suggested that Shenfu injection could treat advanced Non-Small-Cell Lung Cancer (NSCLC) [32].

It has also been found that the method of extraction used can produce different concentrations of the active DAs in vitro [33]. Due to the inherent toxicity of DAs, the dosages found in marketed drugs which also contain Aconiti Lateralis Radix are strictly limited according to the 2015 edition of Chinese Pharmacopoeia. It has also been observed that a small change in the concentration of DAs can have a significant influence on the toxicity and efficiency of Aconiti Lateralis Radix [34]. CYP3A4 is the main metabolizing enzymes of CYP450 in human and is responsible for the metabolism of almost 60% endogenous and exogenous substances [35, 36]. In previous research, many ginsenosides, the active component of P. ginseng, downregulated CYP3A4 expression through inactivation of human pregnant X receptor (PXR) [4, 37–39]. However, the effect of P. ginseng on the metabolism of DAs in vivo has not yet been reported.

Herein, we disclose a refined method to detect DAs in rat blood which contained aconitine, mesaconitine, and hypaconitine. The quantitative concentration range of each component was 0.1-10 ng/mL. The chromatographic behavior of each substance corresponding to signal of MS/MS allowed the simple quantitative and qualitative analysis of each component within the sample. Compared to the previous methods, this method has the advantages of time-saving (the retention time was less than 4.0 min) and low detection concentration, and the sample pretreatment process is simple [11, 24, 40].

In this study, we suggest that P. ginseng can inhibit the clearance of aconitine, mesaconitine, and hypaconitine in rats. This result in the accumulation of aconitine, mesaconitine, and hypaconitine within the body may be the basis of DDI between P. ginseng and Aconiti Lateralis Radix.

As the key toxic and effective components in Aconiti Lateralis Radix, the concentration of DAs is strictly controlled [41]. Pharmacokinetic changes for DAs when there is combined utilization of P. ginseng may lead to a double-sided result. Slowing down the rate of elimination can increase the efficiency of aconitine. However, metabolic inhibition from P. ginseng at DAs toxic dose may delay the detoxification, and the concentration range so far is hard to define. Consequently, it is necessary to study the pharmacokinetic changes and concentration range of aconitine, mesaconitine, and hypaconitine for the combined utilization of P. ginseng and Aconiti Lateralis Radix. In the next work, we would pay more attention to define the safety of the concentration range of DAs when treating with Aconiti Lateralis Radix. In our previous work, we suggested that P. ginseng could downregulate CYP3A4 activities through a combination method. According to the results obtained in this study, we surmise that P. ginseng may inhibit the metabolism of small quantities of aconitine, mesaconitine, and hypaconitine in Aconiti Lateralis Radix thus exerting a dramatic change in calcium ion levels which plays a vital role in excitation-contraction coupling in cardiac myocytes.

Researchers have also found that [3] SFI significantly decreased serum CK, LDH, and TNNI3 levels in myocardial ischemia/reperfusion injury (MIRI) rats, while it significantly increased the level of left ventricular systolic pressure (LVSP), left ventricular diastolic pressure (LVDP), maximal rate of the increase of left ventricular pressure (+dp/dtmax), maximal rate of the decrease of left ventricular pressure (-dp/dtmax), left ventricle ejection fraction percentage (EF), and stroke volume (SV).

Aconitine-type alkaloids associated with Aconiti Lateralis Radix efficacy have lower intake and slower elimination in CHF rats, indicating a noninterdependent relationship between its efficacy and toxicity [42]. Coupled with P. ginseng, aconitine, mesaconitine, and hypaconitine in Aconiti Lateralis Radix may account for the lower intake and slower elimination in the CHF patient; however, this requires further work to be confirmed.

5. Conclusion

A rapid and accurate method to detect the concentration of aconitine, mesaconitine, and hypaconitine in biological samples has been developed and successfully used. From the data obtained in this study, we suggest that P. ginseng could inhibit the metabolism of DAs in vivo. Our findings have important implications for P. ginseng therapy with medicine containing DAs in clinics.

Abbreviations

DAs: | Diester Alkaloids
P. ginseng: | Panax ginseng
UPLC-Q/TOF-MS: | Ultra Performance Liquid Chromatography time-off-flight mass spectrometer
ESI: | Electro spray ionization
DDI: | Drug-drug interaction
SD: | Sprague-Dawley
ACN: | Acetonitrile
MIRI: | Myocardial ischemia/reperfusion injury
NGF: | Nerve growth factor
LVSP: | Left ventricular systolic pressure
LVDP: | Left ventricular diastolic pressure
+dp/dtmax: | Maximal rate of the increase of left ventricular pressure
-dp/dtmax: | Maximal rate of the decrease of left ventricular pressure
EF: | Left ventricle ejection fraction percentage
SFI: | Shenfu injection
LOD: | The limit of detection
LLOQ: | The lowest limit of quantification.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper with any people or organizations.

Acknowledgments

The authors are grateful to Xiangtao Luo and Longfei Li for providing assistance with animal experiments. This work was supported by National Natural Science Foundation of China (Nos. 81630131 and 81673633).

References

Y. Zhang, D. Tian, Y. Huang et al., “Pharmacokinetic evaluation of Shenfu Injection in beagle dogs after intravenous drip administration,” Acta Pharmaceutica Sinica B (APSB), vol. 6, no. 6, pp. 584–592, 2016.

N. Zhang, J. Liu, Z. Qiu, Y. Ye, J. Zhang, and T. Lou, “Shenfu injection for improving cellular immunity and clinical outcome in patients with sepsis or septic shock,” The American Journal of Emergency Medicine, vol. 35, no. 1, pp. 1–6, 2017.

W. Yan-Yan, L. Yan-Yan, L. Lin, Y. Dong-Li, Z. Kun, and L. Yu-Hong, “Protective effects of shenfu injection against myocardial ischemia-reperfusion injury via activation of eNOS in rats,” Biological and Pharmaceutical Bulletin, 2018.

J. L. Raucy, “Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products,” Drug Metabolism and Disposition, vol. 31, no. 5, pp. 533–539, 2003.

H. Xiao, C. Tan, G. Yang, and D. Dou, “The effect of red ginseng and ginseng leaves on the substance and energy metabolism in hypothyroidism rats,” Journal of Ginseng Research, vol. 41, no. 4, pp. 556–565, 2017.

Y. Huang, L. Li, X. Li, S. Fan, P. Zhuang, and Y. Zhang, “Ginseng compatibility environment attenuates toxicity and keeps efficacy in cor pulmonale treated by aconiti lateralis radix beimu incompatibility through the coordinated crosstalk of PKA and Epac signaling pathways,” Frontiers in Pharmacology, vol. 9, article 634, 2018.

H. Zhu, H. Shen, J. Xu et al., “Comparative study on intestinal metabolism and absorption in vivo of ginsenosides in sulphur-fumigated and non-fumigated ginseng by ultra performance liquid chromatography quadruple time-of-flight mass spectrometry based chemical profiling approach,” Drug Testing and Analysis, vol. 7, no. 4, pp. 320–330, 2015.

C. H. Park, S. K. Park, T. W. Seung, D. E. Jin, T. Guo, and H. J. Heo, “Effect of Ginseng (Panax ginseng) Berry EtOAc Fraction on Cognitive Impairment in C57BL/6 Mice under High-Fat Diet Inducement,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 316527, 10 pages, 2015.

L. Zhang, H. Shen, J. Xu et al., “UPLC-QTOF-MS/MS-guided isolation and purification of sulfur-containing derivatives from sulfur-fumigated edible herbs, a case study on ginseng,” Food Chemistry, vol. 246, pp. 202–210, 2018.

J.-S. Shin, H.-W. Park, G. In et al., “Metabolomic approach for discrimination of four- and six-year-old red ginseng (Panax ginseng) using UPLC-QToF-MS,” Chemical & Pharmaceutical Bulletin, vol. 64, no. 9, pp. 1298–1303, 2016.

Y. Xu, Y. Li, P. Zhang et al., “Sensitive UHPLC–MS/MS quantitation and pharmacokinetic comparisons of multiple alkaloids from Fuzi- Beimu and single herb aqueous extracts following oral delivery in rats,” Journal of Chromatography B, vol. 1058, pp. 24–31, 2017.

L. Zhang, X. Lu, J. Wang et al., “Zingiberis rhizoma mediated enhancement of the pharmacological effect of aconiti lateralis radix praeparata against acute heart failure and the underlying biological mechanisms,” Biomedicine & Pharmacotherapy, vol. 96, pp. 246–255, 2017.

P. Zhuang, Y. Huang, Z. Lu et al., “cAMP-PKA-CaMKII signaling pathway is involved in aggravated cardiotoxicity during Fuzi and Beimu Combination Treatment of Experimental Pulmonary Hypertension,” Scientific Reports, vol. 6, no. 1, Article ID 34903, 2016.

M.-Q. Li, C.-G. Pan, X.-M. Wang et al., “Effect of the shenfu injection combined with early goal-directed therapy on organ functions and outcomes of septic shock patients,” Cell Biochemistry and Biophysics, vol. 72, no. 3, pp. 807–812, 2015.

J. Ni, Y. Shi, L. Li et al., “Cardioprotection against Heart Failure by Shenfu Injection via TGF-β/Smads Signaling Pathway,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 7083016, 16 pages, 2017.

S. Wen-Ting, C. Fa-Feng, X. Li et al., “Chinese medicine shenfu injection for heart failure: a systematic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 713149, 25 pages, 2012.

H. Wei, H. Wu, W. Yu, X. Yan, and X. Zhang, “Shenfu decoction as adjuvant therapy for improving quality of life and hepatic dysfunction in patients with symptomatic chronic heart failure,” Journal of Ethnopharmacology, vol. 169, pp. 347–355, 2015.

X. Yan, H. Wu, J. Ren et al., “Shenfu Formula reduces cardiomyocyte apoptosis in heart failure rats by regulating microRNAs,” Journal of Ethnopharmacology, vol. 227, pp. 105–112, 2018.

Z. Mao, Q. Zhang, J. Shang, T. Gao, W. Yuan, and L. Qin, “Shenfu Injection attenuates rat myocardial hypertrophy by up-regulating miR-19a-3p expression,” Scientific Reports, vol. 8, article 4660, 2018.

Q. Zhang, C.-H. Wang, Y.-M. Ma, E.-Y. Zhu, and Z.-T. Wang, “UPLC-ESI/MS determination of 17 active constituents in two categorized formulas of traditional Chinese medicine Sanhuang Xiexin Tang and Fuzi Xiexin Tang application in comparing the differences in decoctions and macerations,” Biomedical Chromatography, vol. 27, no. 8, pp. 1079–1088, 2013.

P. J. Tong, C. L. Wu, X. F. Wang et al., “Development and assessment of a complete-detoxication strategy for Fuzi (lateral root of Aconitum carmichaeli) and its application in rheumatoid arthritis therapy,” Journal of Ethnopharmacology, vol. 146, no. 2, pp. 562–571, 2013.

H. Zhang, S. Sun, W. Zhang et al., “Biological activities and pharmacokinetics of aconitine, benzoylaconine, and aconine after oral administration in rats,” Drug Testing and Analysis, vol. 8, no. 8, pp. 839–846, 2016.

F. Liu, X. Tan, X. Han, X. Li, N. Li, and W. Kang, “Cytotoxicity of Aconitum alkaloid and its interaction with calf thymus DNA by multi-spectroscopic techniques,” Scientific Reports, vol. 7, no. 1, article 14509, 2017.

Q. Zhang, Y. Ma, Z. Wang, and C. Wang, “Pharmacokinetics difference of multiple active constituents from decoction and maceration of Fuzi Xiexin Tang after oral administration in rat by UPLC–MS/MS,” Journal of Pharmaceutical and Biomedical Analysis, vol. 92, pp. 35–46, 2014.

H. Zhang, Z. Wan, X. Yan et al., “Protective effect of Shenfu injection preconditioning on lung ischemia-reperfusion injury,” Experimental and Therapeutic Medicine, vol. 12, no. 3, pp. 1663–1670, 2016.

H. Kim, H. Won, J. Im et al., “Effects of Panax ginseng C.A. Meyer extract on the offspring of adult mice with maternal immune activation,” Molecular Medicine Reports, vol. 18, no. 4, pp. 3834–3842, 2018.

H. Yao, J. Li, Y. Song et al., “Synthesis of ginsenoside Re-based carbon dots applied for bioimaging and effective inhibition of cancer cells,” International Journal of Nanomedicine, vol. Volume 13, pp. 6249–6264, 2018.

S. Y. Han, J. Kim, E. Kim et al., “AKT-targeted anti-inflammatory activity of Panax ginseng calyx ethanolic extract,” Journal of Ginseng Research, vol. 42, no. 4, pp. 496–503, 2018.

C. Y. Dai, P. F. Liu, P. R. Liao et al., “Optimization of flavonoids extraction process in panax notoginseng stem leaf and a study of antioxidant activity and its effects on mouse melanoma B16 Cells,” Molecules, vol. 23, no. 9, 2018.

P. W. Hart, “Shenfu injection after in-hospital cardiac arrest: a question regarding funding,” Critical Care Medicine, vol. 46, no. 3, p. e276, 2018.

C. Liu, Y. Hou, X. Wang et al., “Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial,” Trials, vol. 16, no. 1, article 222, 2015.

A. Cao, H. He, M. Jing et al., “Shenfu injection adjunct with platinum-based chemotherapy for the treatment of advanced non-small-cell lung cancer: a meta-analysis and systematic review,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 1068751, 12 pages, 2017.

Y. Liu, P. Tan, F. Li, and Y. Qiao, “Study on the aconitine-type alkaloids of Radix Aconiti Lateralis and its processed products using HPLC-ESI-MSn,” Drug Testing and Analysis, vol. 5, no. 6, pp. 480–484, 2013.

D.-K. Zhang, R.-S. Li, X. Han et al., “Toxic constituents index: a toxicity-calibrated quantitative evaluation approach for the precise toxicity prediction of the hypertoxic phytomedicine-aconite,” Frontiers in Pharmacology, vol. 7, p. 164, 2016.

Y. Li, J. Ning, Y. Wang et al., “Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects,” Toxicology Letters, vol. 294, pp. 27–36, 2018.

K. Dai, X. J. Yi, and X. J. Huang, “Hepatoprotective activity of iridoids, seco-iridoids and analog glycosides from Gentianaceae on HepG2 cells via CYP3A4 induction and mitochondrial pathway,” Food and Function, vol. 9, no. 5, pp. 2673–2683, 2018.

K. D. Mooiman, R. F. Maas-Bakker, E. E. Moret, J. H. Beijnen, J. H. M. Schellens, and I. Meijerman, “Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction,” Drug Metabolism and Disposition, vol. 41, no. 8, pp. 1494–1504, 2013.

J. Zhang, L. Ding, B. Wang et al., “Notoginsenoside R1 Attenuates Experimental Inflammatory Bowel Disease via Pregnane X Receptor Activation,” The Journal of Pharmacology and Experimental Therapeutics, vol. 352, no. 2, pp. 315–324, 2014.

H. Sun, Y. Yan, Y. Li, and L. Lv, “Reversing effects of ginsenosides on LPS-induced hepatic CYP3A11/3A4 dysfunction through the pregnane X receptor,” Journal of Ethnopharmacology, vol. 229, pp. 246–255, 2019.

S. W. Ng, C. K. Ching, A. Y. W. Chan, and T. W. L. Mak, “Simultaneous detection of 22 toxic plant alkaloids (aconitum alkaloids, solanaceous tropane alkaloids, sophora alkaloids, strychnos alkaloids and colchicine) in human urine and herbal samples using liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 942-943, pp. 63–69, 2013.

G. Huang, L. Yang, Z. Zhang et al., “Human PXR-mediated transcriptional activation of CYP3A4 by Fuzi extracts,” Toxicology Mechanisms and Methods, pp. 1–19, 2018.

B. Yu, Y. Cao, and Y.-K. Xiong, “Pharmacokinetics of aconitine-type alkaloids after oral administration of Fuzi (Aconiti Lateralis Radix Praeparata) in rats with chronic heart failure by microdialysis and ultra-high performance liquid chromatography-tandem mass spectrometry,” Journal of Ethnopharmacology, vol. 165, pp. 173–179, 2015.